BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 33453313)

  • 1. Incidence, risk factors, and CT characteristics of radiation recall pneumonitis induced by immune checkpoint inhibitor in lung cancer.
    Cousin F; Desir C; Ben Mustapha S; Mievis C; Coucke P; Hustinx R
    Radiother Oncol; 2021 Apr; 157():47-55. PubMed ID: 33453313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer.
    Lu X; Wang J; Zhang T; Zhou Z; Deng L; Wang X; Wang W; Liu W; Tang W; Wang Z; Wang J; Jiang W; Bi N; Wang L
    Front Immunol; 2022; 13():918787. PubMed ID: 35795657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications.
    Teng F; Li M; Yu J
    BMC Med; 2020 Sep; 18(1):275. PubMed ID: 32943072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation recall pneumonitis induced by chemotherapy after thoracic radiotherapy for lung cancer.
    Ding X; Ji W; Li J; Zhang X; Wang L
    Radiat Oncol; 2011 Mar; 6():24. PubMed ID: 21375774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiation recall pneumonitis induced by epidermal growth factor receptor-tyrosine kinase inhibitor in patients with advanced nonsmall-cell lung cancer.
    Chiang CL; Chen YW; Wu MH; Huang HC; Tsai CM; Chiu CH
    J Chin Med Assoc; 2016 May; 79(5):248-55. PubMed ID: 27036494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation Recall Pneumonitis Induced by Sintilimab: A Case Report and Literature Review.
    Wang M; Xu S; Zhu H
    Front Immunol; 2022; 13():823767. PubMed ID: 35280981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiation recall pneumonitis triggered by an immune checkpoint inhibitor following re-irradiation in a lung cancer patient: a case report.
    Ye X; Yang J; Stebbing J; Peng L
    BMC Pulm Med; 2022 Feb; 22(1):54. PubMed ID: 35123465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
    Cho JY; Kim J; Lee JS; Kim YJ; Kim SH; Lee YJ; Cho YJ; Yoon HI; Lee JH; Lee CT; Park JS
    Lung Cancer; 2018 Nov; 125():150-156. PubMed ID: 30429014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies.
    Chen X; Sheikh K; Nakajima E; Lin CT; Lee J; Hu C; Hales RK; Forde PM; Naidoo J; Voong KR
    Oncologist; 2021 Oct; 26(10):e1822-e1832. PubMed ID: 34251728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinguishing immune checkpoint inhibitor-related pneumonitis from radiation pneumonitis by CT radiomics features in non-small cell lung cancer.
    Peiliang Wang MD; Yikun Li MM; Mengyu Zhao MM; Jinming Yu MD; Feifei Teng MD
    Int Immunopharmacol; 2024 Feb; 128():111489. PubMed ID: 38266450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study.
    Tiu BC; Zubiri L; Iheke J; Pahalyants V; Theodosakis N; Ugwu-Dike P; Seo J; Tang K; Sise ME; Sullivan R; Naidoo J; Mooradian MJ; Semenov YR; Reynolds KL
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Chu X; Zhao J; Zhou J; Zhou F; Jiang T; Jiang S; Sun X; You X; Wu F; Ren S; Zhou C; Su C
    Lung Cancer; 2020 Dec; 150():76-82. PubMed ID: 33080551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosimetric Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors.
    Bi J; Qian J; Yang D; Sun L; Lin S; Li Y; Xue X; Nie T; Verma V; Han G
    Front Immunol; 2021; 12():828858. PubMed ID: 35095930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation recall pneumonitis from immune checkpoint inhibitors after extra pulmonary radiation.
    Kao LE; Stover D
    Respirol Case Rep; 2023 Oct; 11(10):e01223. PubMed ID: 37731586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and risk factors for pneumonitis among patients with lung cancer who received immune checkpoint inhibitors after palliative thoracic radiotherapy.
    Saito S; Abe T; Iino M; Aoshika T; Ryuno Y; Ohta T; Igari M; Hirai R; Kumazaki Y; Yamaguchi O; Kaira K; Kagamu H; Noda SE; Kato S
    J Radiat Res; 2021 Jul; 62(4):669-675. PubMed ID: 34121123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed cell death 1 (PD-1)/PD-ligand 1(PD-L1) inhibitors-related pneumonitis in patients with advanced non-small cell lung cancer.
    Sun Y; Shao C; Li S; Xu Y; Xu K; Zhang Y; Huang H; Wang M; Xu Z
    Asia Pac J Clin Oncol; 2020 Dec; 16(6):299-304. PubMed ID: 32757454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pneumonitis After Concurrent Chemoradiation and Immune Checkpoint Inhibition in Patients with Locally Advanced Non-small Cell Lung Cancer.
    Altan M; Soto F; Xu T; Wilson N; Franco-Vega MC; Simbaqueba Clavijo CA; Shannon VR; Faiz SA; Gandhi S; Lin SH; Lopez P; Zhong L; Akhmedzhanov F; Godoy MCB; Shroff GS; Wu J; Khawaja F; Kim ST; Naing A; Heymach JV; Daniel-Macdougall C; Liao Z; Sheshadri A
    Clin Oncol (R Coll Radiol); 2023 Oct; 35(10):630-639. PubMed ID: 37507279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of thoracic radiotherapy in patients with prior immune-related adverse events from immune checkpoint inhibitors.
    Shaverdian N; Beattie J; Thor M; Offin M; Shepherd AF; Gelblum DY; Wu AJ; Simone CB; Hellmann MD; Chaft JE; Rimner A; Gomez DR
    Ann Oncol; 2020 Dec; 31(12):1719-1724. PubMed ID: 33010460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased risk of radiation pneumonitis with incidental concurrent use of angiotensin-converting enzyme inhibitors and thoracic radiation therapy.
    Kharofa J; Cohen EP; Tomic R; Xiang Q; Gore E
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):238-43. PubMed ID: 22300564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.